Interpretation of SGLT-2 Inhibitors or GLP-1 Receptor Agonists for Adults with Type 2 Diabetes：a Clinical Practice Guideline

doi:10.12114/j.issn.1007-9572.2021.01.103

Abstract

Abstract: With a comprehensive review of the latest evidence，the BMJ Rapid Recommendations released a clinical practice guideline entitled SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes，thoroughly introducing the selection of the two novel anti-diabetic drugs in adults living with type 2 diabetes. This guideline adopts a risk-based decision-making strategy instead of that based on glycemia or glycosylated hemoglobin control. It provides a visualized summary for both evidence and recommendations to facilitate quick check and shared-decision making for general practitioners.

Key words: Diabetes mellitus, type 2；SGLT-2 inhibitors；GLP-1 receptor agonists；Clinical practice guidelines；Joint doctor-patient decision-making

摘要： BMJ快速推荐栏目结合最新循证医学证据，发布了《SGLT-2抑制剂和GLP-1受体激动剂治疗成人2型糖尿病的临床实践指南》，深入探讨了在成人2型糖尿病患者中选用两种新型降糖药物SGLT-2抑制剂和GLP-1受体激动剂的诊疗策略。该指南采用了基于基线风险，而非基于糖化血红蛋白或血糖控制水平的决策模式。其提供的高度可视化的证据和推荐呈现工具，便于全科医生快速查询，并为医患共同决策提供了可能。

关键词: 糖尿病, 2型；SGLT-2抑制剂；GLP-1受体激动剂；临床实践指南；医患共同决策

AN Kang,LI Sheyu. Interpretation of SGLT-2 Inhibitors or GLP-1 Receptor Agonists for Adults with Type 2 Diabetes：a Clinical Practice Guideline　[J]. Chinese General Practice, 2021, 24(26): 3269-3275. DOI: 10.12114/j.issn.1007-9572.2021.01.103.
安康,李舍予. BMJ快速推荐《SGLT-2抑制剂和GLP-1受体激动剂治疗成人2型糖尿病的临床实践指南》解读[J]. 中国全科医学, 2021, 24(26): 3269-3275. DOI: 10.12114/j.issn.1007-9572.2021.01.103.

References

［1］EINARSON T R，ACS A，LUDWIG C，et al. Prevalence of cardiovascular disease in type 2 diabetes：a systematic literature review of scientific evidence from across the world in 2007-2017［J］. Cardiovasc Diabetol，2018，17（1）：83. DOI：10.1186/s12933-018-0728-6.
［2］侯清涛，李芸，李舍予，等. 全球糖尿病疾病负担现状［J］. 中国糖尿病杂志，2016，24（1）：92-96. DOI：10.3969/j.issn.1006-6187.2016.01.023.
［3］BOMMER C，SAGALOVA V，HEESEMANN E，et al. Global economic burden of diabetes in adults：projections from 2015 to 2030［J］. Diabetes Care，2018，41（5）：963-970. DOI：10.2337/dc17-1962.
［4］WANG L M，GAO P，ZHANG M，et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013［J］. JAMA，2017，317（24）：2515-2523. DOI：10.1001/jama.2017.7596.
［5］RENDERS C M，VALK G D，GRIFFIN S J，et al. Interventions to improve the management of diabetes in primary care，outpatient，and community settings：a systematic review［J］. Diabetes Care，2001，24（10）：1821-1833. DOI：10.2337/diacare.24.10.1821.
［6］OROZCO-BELTRAN D，COS-CLARAMUNT F X. Primary care diabetes in Spain［J］. Prim Care Diabetes，2008，2（2）：101-103. DOI：10.1016/j.pcd.2008.03.001.
［7］ANDRADE L F，RAPP T，SEVILLA-DEDIEU C. Exploring the determinants of endocrinologist visits by patients with diabetes［J］. Eur J Health Econ，2016，17（9）：1173-1184. DOI：10.1007/s10198-016-0794-1.
［8］O'DONNELL M，DE SIúN A，O'MULLANE M，et al. Differences in the structure of outpatient diabetes care between endocrinologist-led and general physician-led services［J］. BMC Health Serv Res，2013，13：493. DOI：10.1186/1472-6963-13-493.
［9］BUSE J B，WEXLER D J，TSAPAS A，et al. 2019 update to：management of hyperglycemia in type 2 diabetes，2018. A consensus report by the American Diabetes Association（ADA）and the European Association for the Study of Diabetes（EASD）［J］. Diabetes Care，2020，43（2）：487-493. DOI：10.2337/dci19-0066.
［10］GARBER A J，HANDELSMAN Y，GRUNBERGER G，et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary［J］. Endocr Pract，2020，26（1）：107-139. DOI：10.4158/cs-2019-0472.
［11］COSENTINO F，GRANT P J，ABOYANS V，et al. 2019 ESC Guidelines on diabetes，pre-diabetes，and cardiovascular diseases developed in collaboration with the EASD［J］. Eur Heart J，2020，41（2）：255-323. DOI：10.1093/eurheartj/ehz486.
［12］DAS S R，EVERETT B M，BIRTCHER K K，et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes：a report of the American college of cardiology solution set oversight committee［J］. J Am Coll Cardiol，2020，76（9）：1117-1145. DOI：10.1016/j.jacc.2020.05.037.
［13］Kidney Disease：Improving Global Outcomes（KDIGO） Diabetes Work Group.KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease［J］. Kidney Int，2020，98（4S）：S1-115. DOI：10.1016/j.kint.2020.06.019.
［14］UTZ B，DE BROUWERE V.“Why screen if we cannot follow-up and manage?” Challenges for gestational diabetes screening and management in low and lower-middle income countries：results of a cross-sectional survey［J］. BMC Pregnancy Childbirth，2016，16（1）：341. DOI：10.1186/s12884-016-1143-1.
［15］PERKOVIC V，JARDINE M J，NEAL B，et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy［J］. N Engl J Med，2019，380（24）：2295-2306. DOI：10.1056/NEJMoa1811744.
［16］ZINMAN B，WANNER C，LACHIN J M，et al. Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes［J］. N Engl J Med，2015，373（22）：2117-2128. DOI：10.1056/NEJMoa1504720.
［17］GERSTEIN H C，COLHOUN H M，DAGENAIS G R，et al. Dulaglutide and renal outcomes in type 2 diabetes：an exploratory analysis of the REWIND randomised，placebo-controlled trial［J］. Lancet，2019，394（10193）：131-138. DOI：10.1016/S0140-6736（19）31150-X.
［18］MARSO S P，DANIELS G H，BROWN-FRANDSEN K，et al. Liraglutide and cardiovascular outcomes in type 2 diabetes［J］. N Engl J Med，2016，375（4）：311-322. DOI：10.1056/NEJMoa1603827.
［19］LI S，VANDVIK P O，LYTVYN L，et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes：a clinical practice guideline［J］. BMJ，2021，373：n1091. DOI：10.1136/bmj.n1091.
［20］National Institute for Health and Care Excellence. Type 2 diabetes in adults：management（NICE guideline NG28）［EB/OL］. （2015-12-02）［2021-06-22］. https：//www.nice.org.uk/Guidance/NG28.
［21］中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）［J］. 中华糖尿病杂志，2021，13（4）：315-409. DOI：10.3760/cma.j.cn115791-20210221-00095.　
［22］YANG X L，LI J X，HU D S，et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population：the China-PAR project（prediction for ASCVD risk in China）［J］. Circulation，2016，134（19）：1430-1440. DOI：10.1161/CIRCULATIONAHA.116.022367.
［23］中华医学会糖尿病学分会，中华医学会内分泌学分会.中国成人2型糖尿病患者糖化血红蛋白控制目标及达标策略专家共识［J］. 中华糖尿病杂志，2020，12（1）：1-12. DOI：10.3760/cma.j.issn.1674-5809.2020.01.001.　
［24］GUYATT G H，OXMAN A D，VIST G E，et al. GRADE：an emerging consensus on rating quality of evidence and strength of recommendations［J］. BMJ，2008，336（7650）：924-926. DOI：10.1136/bmj.39489.470347.AD.
［25］RODRIGUEZ-GUTIERREZ R，GIONFRIDDO M R，OSPINA N S，et al. Shared decision making in endocrinology：present and future directions［J］. Lancet Diabetes Endocrinol，2016，4（8）：706-716. DOI：10.1016/S2213-8587（15）00468-4.
［26］PALMER S C，TENDAL B，MUSTAFA R A，et al. Sodium-glucose cotransporter protein-2（SGLT-2）inhibitors and glucagon-like peptide-1（GLP-1）receptor agonists for type 2 diabetes：systematic review and network meta-analysis of randomised controlled trials［J］. BMJ，2021，372：m4573. DOI：10.1136/bmj.m4573.
［27］LIU J L，LI L，LI S Y，et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes：a systematic review and meta-analysis of randomized controlled trials［J］. Diabetes Obes Metab，2020，22（9）：1619-1627. DOI：10.1111/dom.14075.
［28］UEDA P，SVANSTR?M H，MELBYE M，et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events：nationwide register based cohort study［J］. BMJ，2018，363：k4365. DOI：10.1136/bmj.k4365.
［29］LUPSA B C，INZUCCHI S E. Use of SGLT-2 inhibitors in type 2 diabetes：weighing the risks and benefits［J］. Diabetologia，2018，61（10）：2118-2125. DOI：10.1007/s00125-018-4663-6.
［30］NEAL B，PERKOVIC V，MAHAFFEY K W，et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes［J］. N Engl J Med，2017，377（7）：644-657. DOI：10.1056/NEJMoa1611925.
［31］GUERCI B，CHARBONNEL B，GOURDY P，et al. Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings［J］. Diabetes Metab，2019，45（6）：528-535. DOI：10.1016/j.diabet.2019.01.006.
［32］ELASHOFF M，MATVEYENKO A V，GIER B，et al. Pancreatitis，pancreatic，and thyroid cancer with glucagon-like peptide-1-based therapies［J］. Gastroenterology，2011，141（1）：150-156. DOI：10.1053/j.gastro.2011.02.018.
［33］MALI G，AHUJA V，DUBEY K. Glucagon-like peptide-1 analogues and thyroid cancer：an analysis of cases reported in the European pharmacovigilance database［J］. J Clin Pharm Ther，2021，46（1）：99-105. DOI：10.1111/jcpt.13259.
［34］LI L，SHEN J T，BALA M M，et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus：systematic review and meta-analysis of randomised and non-randomised studies［J］. BMJ，2014，348：g2366. DOI：10.1136/bmj.g2366.
［35］MATCH-IT［EB/OL］. ［2021-06-22］. https：//magicevidence.org/solutions/match-it/.
［36］BMJ Rapid Recommendations：Sodium-Glucose Transport Protein 2（SGLT-2） inhibitors and Glucagon-Like Peptide-1（GLP-1）［EB/OL］. （2021-05-11）［2021-06-22］. https：//app.magicapp.org/#/guideline/j1Wqrn.
［37］GUYATT G H，OXMAN A D，KUNZ R，et al. GRADE guidelines：8.Rating the quality of evidence--indirectness［J］. J Clin Epidemiol，2011，64（12）：1303-1310. DOI：10.1016/j.jclinepi.2011.04.014.
［38］HEEN A F，VANDVIK P O，AGORITSAS T，et al. Including practical issues and patient perspectives in Rapid Recommendations［J］. BMJ，2018，363：k4871. DOI：10.1136/bmj.k4871.

[1]	LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301.
[2]	LIN Kai, YAO Mi, CHEN Zhang, JI Xinxin, LIN Runqi, CHEN Yongsong, Sim MOIRA. Conceptual Framework and Responding Approach of Treatment Burden of Type 2 Diabetes: a Video Recording-based Analysis [J]. Chinese General Practice, 2023, 26(34): 4302-4307.
[3]	YANG Hui, HU Ruwei, LIU Ruqing, LU Junfeng, WU Jinglan. Relationship between Community Health Service Experience and Glycemic Control Outcomes in Patients with Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(34): 4290-4295.
[4]	ZHANG Juan, LI Haifen, LI Xiaoman, YAO Miao, MA Huizhen, MA Qiang. Construction of Recurrence Risk Prediction Model for Diabetic Foot Ulcer on the Basis of Logistic Regression, Support Vector Machine and BP Neural Network Model [J]. Chinese General Practice, 2023, 26(32): 4013-4019.
[5]	CHENG Jingwei, QIAO Junjun, YIN Zhen, HU Junpeng, WANG Qinghe, LIU Yangqing, WANG Yanfang. Interpretation of ISPAD Clinical Practice Consensus Guidelines 2022: Exercise in Children and Adolescents with Diabetes [J]. Chinese General Practice, 2023, 26(30): 3719-3724.
[6]	ZHOU Xiaoqi, LIU Xinhui, ZHANG Wei, LI Changfeng, YAN Yaqiong. Association of Alanine Transaminase and Aspartate Aminotransferase/Alanine Transaminase Ratio with Type 2 Diabetes and Metabolic Syndrome in the Elderly [J]. Chinese General Practice, 2023, 26(29): 3645-3649.
[7]	ZHAO Xiaohua, DU Lin, GAO Shengnan, JIANG Ziyun. Multiple Deep Muscle Abscesses in Type 2 Diabetes in the Elderly: Report of One Case and Literature Review [J]. Chinese General Practice, 2023, 26(29): 3715-3718.
[8]	LUO Dan, XU Jingjing, WANG Yubing, LI Mingzi, FORBES Angus. Development and Preliminary Practice of Resilience-oriented Structured Treatment and Educational Program for Adolescents with Type 1 Diabetes [J]. Chinese General Practice, 2023, 26(27): 3423-3429.
[9]	DONG Yanan, JIANG Xiaorui, WANG Kai, ZONG Chuanchong, LIN Guodong, LI Xiangqing, LIN Chunxiao, CHI Juntao. The Effect of Modified Tibial Transverse Transport Technique in the Treatment of Wagner Grade Ⅲ and Ⅳ Diabetic Foot Patients [J]. Chinese General Practice, 2023, 26(27): 3411-3416.
[10]	LU Zuowei, CAO Hongwei, LIU Tao, ZHANG Nana, CHEN Yanyan, SHI Qinli, LIU Xiangyang, WANG Qiong, LAI Jingbo, LI Xiaomiao. Development and Validation of a Risk Prediction Model for the Progression from Microalbuminuria to Macroalbuminuria in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(26): 3259-3268.
[11]	GU Yunjie, SONG Jing, YIN Jun. Clinical Study on Low-carbon Diet for Endogenous-insulin-deficient Diabetes Patients [J]. Chinese General Practice, 2023, 26(26): 3308-3313.
[12]	KONG Dexian, XING Yuling, SUN Wenwen, ZHANG Zhimin, ZHOU Fei, MA Huijuan. Correlation between Estimated Glucose Disposal Rate and Metabolism-associated Fatty Liver Disease in Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(26): 3252-3258.
[13]	CHEN Lunwen, ZHOU Yang, YAN Guodong, SHEN Yi, SUN Chen, CAI Wanli, CHU Minjie, XIAO Jing. Risk of Malignant Tumor in Patients with Type 2 Diabetes: a Prospective Population-based Study [J]. Chinese General Practice, 2023, 26(26): 3238-3245.
[14]	FEI Sijie, ZHANG Qiang, LIU Fangfang, BAI Lu, SUN Caihong, XIN Caifeng. Correlation between Glycated Hemoglobin Variability and New-onset Atrial Fibrillation in Type 2 Diabetes Patients Combined with Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2023, 26(26): 3246-3251.
[15]	HE Rong, ZHANG Li, LI Peng, ZHANG Xiaoling, ZHANG Guo, ZANG Yiran, WU Shouling, SUN Lixia. Immediate Effects of Aerobic Exercise on Arterial Stiffness in a Male Population with Different Blood Glucose Levels [J]. Chinese General Practice, 2023, 26(24): 2997-3004.